Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | F2R | P25116 | 9/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24478307 | 0.85 | MAPT (0.50) | RAB9ANPC1MAPTSTAT1SMN1; SMN2 | |
| SCHEMBL10265073 | 0.82 | NPC1 (0.49) | RAB9ANPC1MAPTSTAT1SMN1; SMN2 | |
| SCHEMBL16994755 | 0.82 | KMT2A (0.48) | RAB9ANPC1MAPTSMN1; SMN2USP30 | |
| SCHEMBL10265353 | 0.81 | NPC1 (0.48) | RAB9ANPC1MAPTSTAT1SMN1; SMN2 | |
| SCHEMBL4409348 | 0.78 | MEN1 (0.50) | RAB9ANPC1MAPTSMN1; SMN2USP30 | |
| SCHEMBL640841 | 0.76 | F2R (0.48) | RAB9ANPC1MAPTSTAT1SMN1; SMN2 | |
| SCHEMBL4508468 | 0.76 | F2R (0.51) | RAB9ANPC1MAPTSTAT1SMN1; SMN2 | |
| SCHEMBL640228 | 0.75 | F2R (0.50) | RAB9ANPC1MAPTSTAT1SMN1; SMN2 | |
| SCHEMBL1580717 | 0.74 | F2R (0.50) | RAB9ANPC1MAPTSTAT1SMN1; SMN2 | |
| SCHEMBL20884575 | 0.72 | MAPT (0.56) | MAPTSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | RAB9A 2487/4885NPC1 949/4885MAPT 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.